Abstract
Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.
| Original language | English |
|---|---|
| Pages (from-to) | 660-666 |
| Number of pages | 7 |
| Journal | British journal of cancer |
| Volume | 111 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 Aug 12 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. / Kang, Y. K.; Rha, S. Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y. J.
In: British journal of cancer, Vol. 111, No. 4, 12.08.2014, p. 660-666.Research output: Contribution to journal › Article
TY - JOUR
T1 - A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
AU - Kang, Y. K.
AU - Rha, S. Y.
AU - Tassone, P.
AU - Barriuso, J.
AU - Yu, R.
AU - Szado, T.
AU - Garg, A.
AU - Bang, Y. J.
PY - 2014/8/12
Y1 - 2014/8/12
N2 - Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.
AB - Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2-6 (Arm A) or pertuzumab 840 mg q3w for six cycles (Arm B). Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity. The co-primary endpoints were day 43 pertuzumab serum trough concentration (C min) and safety.Results:Thirty patients were randomised. Mean pertuzumab C min at day 43 was 40.0 μg ml-1 (s.d.: 17.3) in Arm A and 62.7 μg ml-1 (29.1) in Arm B. Mean day 43 C min in Arm A was ∼37% lower than that seen in metastatic breast cancer. The safety profiles were similar between arms and treatment was well tolerated. Partial responses were achieved by 86% and 55% of patients in Arms A and B, respectively.Conclusions:On the basis of the pharmacokinetic and safety data, the 840 mg q3w pertuzumab dose has been selected for a phase III study of pertuzumab, trastuzumab and chemotherapy in HER2-positive aGC.
UR - http://www.scopus.com/inward/record.url?scp=84906092045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906092045&partnerID=8YFLogxK
U2 - 10.1038/bjc.2014.356
DO - 10.1038/bjc.2014.356
M3 - Article
C2 - 24960402
AN - SCOPUS:84906092045
VL - 111
SP - 660
EP - 666
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 4
ER -